公开(公告)号：US20240165047A1

公开(公告)日：2024-05-23

申请号：US18282410

申请日：2022-08-11

申请人： Chengdu Jinrui Foundation Biotech Co., Ltd.

发明人： Wenbin Li ,  Ce Wang ,  Xintian Lai ,  Xiaobo Wang

IPC分类号： A61K31/05 ,  A61K9/00 ,  A61K9/127 ,  A61P35/00

CPC分类号： A61K31/05 ,  A61K9/0019 ,  A61K9/127 ,  A61P35/00

摘要： The present invention relates to a medical use of honokiol, and in particular to a use of honokiol in the preparation of a drug for treating a meningioma. Experiments prove that honokiol can effectively inhibit the growth of a meningioma, and eliminate and/or reduce lesions of the meningioma. Moreover, clinical experiments show that the safety and tolerance of honokiol are good.

公开(公告)号：US20220096394A1

公开(公告)日：2022-03-31

申请号：US17276568

申请日：2020-12-10

申请人： Chengdu Jinrui Foundation Biotech Co., Ltd. ,  Beijing Tiantan Hospital, Capital Medical University

发明人： Wenbin Li ,  Shenglan Li ,  Neng Qiu ,  Haoyu Ye

IPC分类号： A61K31/05 ,  A61P17/14 ,  A61P35/00

摘要： The invention involves the pharmaceutical use of honokiol, in particular the use of honokiol in inhibiting medulloblastoma, and it has been experimentally proved that honokiol can inhibit the proliferation and induce cell cycle arrest and apoptosis of medulloblastoma cells; promoting hair growth, and it has been experimentally proved that honokiol can promote hair growth and has no toxic and side effects on liver and kidney; and promoting white hair blackening, and it has been experimentally proved that honokiol can promote white hair blackening and has no toxic side effects on liver and kidney.